There is a counter conservative reasoning, and that is timing a smooth transition form clinics and clinical manufacturing into early access and ultimately commercial manufacturing.
One does not want to lose the momentum, personnel and strong contacts associated with this phase three trial as it hopefully transitions into commercialization.
I could go on far better than any bear here on missed deadlines, but they all made sense to one degree or another, and so I do not question investors like you putting their expectations on a slow boat to China, but at some point in trials, facts and reality, not words take over. Whether we end sooner or later will be dictated primarily by science and next by pragmatic commercialization realities. IMHO.
News 
Market Data 
Discover 
